Both point mutations and deletions of the MYT1L gene as well as microdeletions of chromosome band 2p25.3 including MYT1L are associated with intellectual disability, obesity, and behavioral problems. Thus, MYT1L is assumed to be the-at least mainlycausative gene in the 2p25.3 deletion syndrome. Here, we present comprehensive descriptions of nine novel individuals bearing MYT1L mutations; most of them single nucleotide variants (SNVs). This increases the number of known individuals with causative deletions or SNVs of MYT1L to 51. Since eight of the nine novel patients bear mutations affecting MYT1L only, the total number of such individuals now nearly equals the number of individuals with larger microdeletions affecting additional genes, allowing for a comprehensive phenotypic comparison of these two patient groups. For example, 55% of the individuals with mutations affecting MYT1L only were overweight or obese as compared to 86% of the individuals with larger microdeletions. A similar trend was Isabelle C. Windheuser, Jessica Becker, and Kirsten Cremer contributed equally as first authors. Roberto Colombo, Maja Hempel, and Hartmut Engels contributed equally as senior authors.
observed regarding short stature with 5 versus 35%, respectively. However, these differences were nominally significant only after correction for multiple testing, further supporting the hypothesis that MYT1L haploinsufficiency is central to the 2p25.3 deletion phenotype. Most importantly, the large number of individuals with MYT1L mutations presented and reviewed here allowed for the delineation of a more comprehensive clinical picture. Seizures, postnatal short stature, macrocephaly, and microcephaly could be shown to be over-represented among individuals with MYT1L mutations. well as obesity or overweight. The facial phenotype does not seem to be recognizable. Up to now, the most frequent type of variation described for MYT1L are microdeletions which often include additional genes while considerably less individuals with single nucleotide variants (SNVs) of MYT1L have been reported (Al Tuwaijri & Alfadhel, 2019; Becker, Jaggard, & Horrocks, 2010; Blanchet et al., 2017; Bonaglia, Giorda, & Zanini, 2014; de Ligt et al., 2012; De Rocker et al., 2015; Doco-Fenzy et al., 2014; Loid et al., 2018; Mayo et al., 2015; Rio et al., 2013; Stevens et al., 2011; Wang et al., 2016) . MYT1L has been shown to be the main causative gene in such submicroscopic deletions of chromosome band 2p25.3 (Blanchet et al., 2017; De Rocker et al., 2015) . A previous comparison of individuals with MYT1L deletion versus MYT1L SNVs identified no significant difference regarding the main clinical features (Blanchet et al., 2017) .
Here, we present a comprehensive clinical characterization of nine novel individuals from eight families bearing MYT1L mutations. Six of the novel variants are SNVs or small indels and two are microdeletions.
To our knowledge, this increases the number of known individuals with MYT1L mutations to 51. Based on this large number, certain features such as postnatal short stature could be identified as significantly overrepresented among individuals with MYT1L mutations. Additionally, an even distribution between individuals carrying mutations affecting MYT1L only (SNVs, indels, and small microdeletions) and individuals with larger microdeletions affecting additional genes is achieved. A comparison of the proportions of individuals with certain clinical features between these two groups was performed.
| MATERIALS AND METHODS
All individuals presented here were originally ascertained during genetic counseling or genetic diagnostics with ID/DD as the most frequent and prominent reason. Additional reasons for ascertainment were behavioral issues (two individuals) and, for example, microcephaly, seizures or obesity (one individual each).
Individuals 1 and 2 were identified in a study to elucidate new candidate ID genes by trio whole exome sequencing (WES) in a cohort of 311 individuals with unexplained ID and their unaffected parents.
The inclusion criteria were ID/DD with or without additional features (e.g., craniofacial dysmorphism, organ malformation, etc.) which could not be attributed to a clinically recognizable syndrome by an experienced clinical geneticist. Clinically relevant chromosomal aberrations were excluded by chromosome microarray analysis (CMA). Written informed consent to the study and to the publication of the clinical photographs was obtained from the legal representatives. All investigations were performed in accordance with the protocols of the Declaration of Helsinki and were approved by the local institutional review board (Ethics Committee of the Medical Faculty of the University of Bonn, approvals 131/08 and 024/12). WES was performed as published previously (Schafgen et al., 2016) .
Trio WES with DNA samples of individuals 3, 4, 5, and 8 as well as of their healthy parents was performed after written informed consent as described previously (Hempel et al., 2015) .
WES of individuals 6a (son) and 6b (father) as well as their unaffected mother/wife and sister/daughter was performed after written consent as published previously (Youssefian et al., 2019) . Genomic variants were filtered and prioritized according to the following criteria: heterozygous presence in the affected father and son and absence in the unaffected mother and daughter; gene reported to be involved in neurologic or mental disorders; frequency in publicly available variant databases <0.01%; and in silico predicted pathogenic effect of the variant.
Sanger sequencing was performed by standard methods to confirm all MYT1L sequence variants and their de novo status or in the case of individuals 6a and b its parental origin. Primer sequences are available upon request. The Combined Annotation Dependent Depletion tool (CADD, version GRCh37-v1.4, [Kircher et al., 2014] ) was used to determine the potential pathogenicity of the identified variants. Statistical significance of the differences in frequencies between two patient groups with different mutation types was calculated for five features (presence or absence of short stature, microcephaly and overweight/obesity at last examination, presence or absence of seizures, and autism spectrum disorder; ASD) using Fisher's exact test.
Bonferroni correction for multiple testing (n = 5) yielded a corrected p value of p ≤ .01 as significance threshold. Age distribution at last examination was compared between the "MYT1L only" patient group (median/M = 13.07, SD = 11.43) and the group of patients with "larger microdeletions" (M = 18.35, SD = 17.4). This comparison did not reveal significant difference between the two groups (t test, p = .22). For one patient, no information on age was provided in the original study (Wang et al., 2016) . 3 | CASE REPORTS AND RESULTS
| Case reports and genetic testing
Main findings and measurements at last examination are given in At the age of 2 years, a temporary mild hypothyroidism was diagnosed and he was treated with L-thyroxine for 2 years. Examinations of his eyes, teeth, metabolic system, sleep-EEG, brain MRI, and audiology gave normal results.
He attended a school for children with special needs. At the first clinical genetic assessment at the age of 6 6 / 12 years, he presented with microcephaly (OFC 49.5 cm, −2.2 SD) and clinodactyly ( Figure 1 ).
Other measurements were normal (weight 20 kg, −1.0 SD; height 116 cm, −1.1 SD; BMI 14.9 kg/m 2 , −0.4 SD). His parents had normal head circumferences (mother 55 cm, father 57.5 cm). In the last clinical assessment at 12 with nocturnal awakenings, and persisting muscular hypotonia.
According to the mother, she measured 170 cm (+3.7 SD) and 106 kg (+4.0 SD, BMI: 36.7 kg/m 2 , +3.3 SD) at the age of 10 9 / 12 years and menarche was at age 10 years. She attends a special school for mentally handicapped children and cannot read nor write, except her name.
EEGs, brain MRI, audiometry, basic metabolic investigations, con- Extended metabolic work up in blood, urine and CSF as well as MRI of brain and spinal cord gave normal results. SSEP showed slightly elevated latency in response to right n. tibialis stimulation.
CMA gave normal results. Individual 6a was delivered at gw 37 + 2 by cesarean section after a normal pregnancy. Birth length (47 cm, −1.5 SD) and head circumference (32 cm, −1.7 SD) were within the lower range, and his weight was 3,700 g (+1.2 SD). His development was delayed, especially concerning speech and language. At 2 3 / 12 years he spoke <25 words clearly and did not form sentences. Receptive language was impaired with difficulties in playing with other children. Hearing impairment was excluded. His motor development was mildly delayed (independent sitting and walking at the age of 11 and 19 months, respectively).
He tended to display destructive behavior. Two febrile seizures occurred at Ages 3 and 5 years. EEG showed abnormal peak waves but was inconclusive. He had a history of hypotonia and feeding prob- (Lys1040*), CADD 46.0] in MYT1L was identified both in the affected father and son, but not in the unaffected mother and daughter.
Individual 7 is the first of three children of healthy unrelated parents. She was born after uneventful pregnancy at gw 38 by normal delivery. Her birth weight was 3,130 g (−0.1 SD) and her OFC at birth was 33.5 cm (−0.6 SD). Her birth length is unknown. Her OFC at 6 weeks was 37 cm (−0.3 SD) and at 33 weeks it was 41.5 cm (−2.4 SD).
She had normal gross motor developmental milestones, but her fine motor skills were delayed. Her early speech development was normal but her speech remained unclear and needed speech and language therapy because of pronunciation difficulties. She was referred to the pediatrician at the age of 4 ½ years because of concerns about sensory behaviors, poor fine motor skills and issues regarding social interactions. A cognitive assessment showed a verbal IQ of 75 and a performance IQ of 67. She had autistic features with ritualistic behavior and a very good memory for images. She was diagnosed with atypical autism. At the last examination at the age of 9 years, measurements were normal. She had mild facial dysmorphism with a long face, cupid bows, and upslanting palpebral fissures (Figure 1 ).
First signs of puberty were early, at the age of 9 years. She had increased TSH with normal T4 and no indication for thyroid treatment at that stage.
CMA identified a 0.43 Mb deletion on the short arm of chromosome 2 at p25.3 which was confirmed by FISH studies. It affects only Exons 1 and 2 of the MYT1L gene. The deletion was shown to be de novo.
Individual 8 is the fourth child of healthy non-consanguineous parents and was born after an uneventful pregnancy at gw 37 + 6 GW by re-re-cesarean section with normal measurements (weight 3,120 g, −0.4 SD; length 51 cm, 0 SD; OFC 34.5 cm, −0.2 SD). After an unremarkable development in the first months of life, muscular hypotonia, and delays in motor and speech development became obvious.
He started sitting with 1 year and walking at the age of 2.5 years. At the age of 3 10 / 12 years he spoke only two words with an impaired receptive language development. He hardly understood and followed instructions and did not interact with other children. He had myopia and strabismus, but did not accept wearing glasses.
The last examination at age 4 2 / 12 years showed a friendly but reclusive boy with normal measurements and minor dysmorphic fea- 
| Frequency comparison of findings in two patient groups with different mutation types
To our knowledge, our study increases the number of published individuals with MYT1L deletions or SNVs to 51 (Al Tuwaijri & Alfadhel, 2019; Becker et al., 2010; Blanchet et al., 2017; Bonaglia et al., 2014; De Rocker et al., 2015; Doco-Fenzy et al., 2014; Loid et al., 2018; Mayo et al., 2015; Rio et al., 2013; Stevens et al., 2011; Wang et al., 2016, DECIPHER patient 141 and that of individuals with microdeletions affecting additional genes.
These two groups of individuals will be referred to as "MYT1L only"
and "larger microdeletions" from now on. Significance of the frequency differences between the two groups of individuals was calcu- 
| DISCUSSION
In 2011, MYT1L was first proposed as the causative gene in 2p25.3 microdeletions and MYT1L haploinsufficiency as a cause for ID (Stevens et al., 2011) . were strikingly similar to the individuals with larger deletions, the authors hypothesized that MYT1L is the causal gene for both observed phenotypes. A further case report described an individual with a de novo intragenic deletion of MYT1L and DD, microcephaly, behavioral problems, and stereotypies, but without obesity at an age of 4.5 years (Mayo et al., 2015) . In 2017, Blanchet and colleagues published the next larger series of novel patients with ID/DD, reviewed the clinical phenotype and compared the clinical pictures of SNV mutation carriers with that of microdeletion carriers (Blanchet T A B L E 2 Frequency comparison of findings between the two patient groups with different mutation types of MYT1L ("MYT1L only" microdeletions and SNVs vs. "larger microdeletions") for five features (presence or absence at last examination of short stature, microcephaly and overweight/obesity, presence or absence of seizures, and ASD) using Fisher's exact test , 2017) . In addition to one individual with a microdeletion, nine individuals with de novo MYT1L SNVs were reported. The authors then compared the proportions of individuals with the phenotypes ID, gross motor delay, speech delay, autism, overweight/obesity, or hyperphagia between 28 published and own individuals with deletions affecting MYT1L and 11 published and own individuals with MYT1L
SNVs (Bonaglia et al., 2014; De Rocker et al., 2015; Doco-Fenzy et al., 2014; Stevens et al., 2011) . No significant differences between the groups were found for any of the clinical features, supporting the hypothesis that MYT1L haploinsufficiency is central to the 2p25.3 deletion phenotype. The overall proportion of individuals with overweight or obesity was 85%.
Here, we present nine novel individuals with MYT1L mutations.
The clinical findings of these novel individuals largely confirmed the above-named clinical picture. All nine individuals had developmental delay and (borderline) ID, six had muscular hypotonia, and four had (febrile) seizures. Behavioral anomalies were seen in seven of them and ASD in two. Only three of the nine individuals developed overweight/obesity postnatally. Thus, the frequency for overweight/obesity among these novel individuals is lower than reported before with 33% as compared to, for example, the 85% reported earlier (Blanchet et al., 2017) . Severe congenital malformations were absent and craniofacial dysmorphism was generally mild. data may constitute a-however to date definitely insignificant-hint at a higher overall incidence of postnatal short stature and overweight/obesity in the patient group with additional deleted genes.
Additional studies with even larger samples of individuals with different MYT1L variation are necessary.
Seizures were described in 76.2% of all individuals with no difference between groups (MYT1L only: 8/12, larger microdeletions 8/9, p = .338). While the overall proportion of different behavioral anomalies is very similar for both groups (95.8 vs. 100%), there seems to be a difference for the presence of ASD. This proportion seems to be significantly higher in the "MYT1L only" group with 66.7% (12/18) than in the "larger microdeletions" group with 21.1% (4/19, p = .008). However, this should be interpreted with utmost caution since ASD is much more prone to ascertainment differences than features which are determined more easily and more comprehensively such as body measurements. The overall proportion of individuals with reported ASD is 43.2% and thus slightly higher than the one reported by Blanchet and colleagues.
We were also interested in the localization of the many different mutations within MYT1L (Figure 2) . The nonsense and frameshift variants do not seem to show any clustering or preferential localizations.
Even the rather N-terminal nonsense mutations of Individuals 6a and 6b do not seem to be associated with a distinguishable clinical picture.
A possible explanation for this may be mRNA NMD as opposed to truncation which would more likely give rise to distinguishable clinical pictures caused by proteins of different lengths and domain contents.
However, this hypothesis could not be analyzed for lack of suitable patient material. Equally, we could not find evidence for preferential deletions of certain regions of the gene neither for deletions within the gene nor for deletions affecting the N-or the C-terminus of the gene (Figure 2 ) or for different deletion localizations being associated with different clinical pictures. Interestingly, all seven known missense variants (identified in eight individuals) are localized in the second and third zinc finger domains and therefore are likely to interfere with DNA binding (Figures 2 and 3) .
In summary, we present nine novel individuals from eight families with different types of mutations affecting MYT1L, seven of them with SNVs affecting MYT1L and two of them with microdeletions affecting either MYT1L only or MYT1L and additional genes. Seven of the individuals carry de novo mutations and one SNV is shared by an affected son and his affected father in whose case the origin of the mutation could not be analyzed.
Our study gives the most comprehensive picture of the clinical appearance of individuals with MYT1L mutations so far. The typical clinical picture of ID/DD together with frequent overweight or obesity is confirmed. Overweight/obesity is present in 70.5% of individuals and thus slightly less frequent than reported before. Altogether, the number of affected individuals now is 51, allowing for the most comprehensive clinical picture yet. Thus, several clinical findings such as seizures, short stature, macrocephaly, and microcephaly which have not been in the focus so far could be shown to be clearly overrepresented among individuals with MYT1L mutations.
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